Cargando…
Serum Protein Pattern Could Predict the Therapeutic Effect of First-Line Pemetrexed/Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma
BACKGROUND: In patients with advanced non-squamous non-small cell lung cancer (NSCLC), a pemetrexed/cisplatin (PP) regimen is considered as one of the preferred first-line treatments. However, only about half of the treated patients respond, and there is no clinically useful marker that can predict...
Autores principales: | Shen, Hong, Fang, Xue-Feng, Yuan, Ying, Yang, Jiao, Zheng, Shu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649948/ https://www.ncbi.nlm.nih.gov/pubmed/29147418 http://dx.doi.org/10.14740/wjon901w |
Ejemplares similares
-
Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy
por: MOU, WENJUN, et al.
Publicado: (2014) -
Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review
por: He, Guangzhao, et al.
Publicado: (2016) -
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021) -
Therapeutic effects of sequential chemoradiotherapy with pemetrexed and cisplatin on locally advanced laryngeal cancer
por: Tao, Youmao, et al.
Publicado: (2016) -
Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
por: Jia, Bo, et al.
Publicado: (2020)